Streetbeat News

Price Targets

PSTG

B of A Securities analyst Wamsi Mohan maintains a Neutral rating on Pure Storage (NYSE:PSTG) and raises the price target from $33 to $38.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 11:05 am

WRN

HC Wainwright & Co. analyst Heiko Ihle maintains a Buy rating on Western Copper & Gold (AMEX:WRN) and raises the price target from $3.5 to $3.75.

Portfolio Pulse from richadhand@benzinga.com

August 28, 2023 | 10:43 am

ESPR

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $22 price target.

Portfolio Pulse from richadhand@benzinga.com

August 28, 2023 | 10:41 am

OKTA

Wells Fargo analyst Andrew Nowinski maintains an Overweight rating on Okta (NASDAQ:OKTA) but has lowered the price target from $98 to $85.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 10:38 am

CRWD

Wells Fargo analyst Andrew Nowinski maintains an Overweight rating on CrowdStrike Holdings (NASDAQ:CRWD) and raises the price target from $175 to $200.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 10:37 am

INTU

Citigroup analyst Steven Enders maintains a Buy rating on Intuit (NASDAQ:INTU) and raises the price target from $495 to $565.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 10:35 am

AKBA

HC Wainwright & Co. analyst Ed Arce has upgraded Akebia Therapeutics from Neutral to Buy and raised the price target from $2 to $3.75.

Portfolio Pulse from richadhand@benzinga.com

August 28, 2023 | 10:30 am

BTAI

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on BioXcel Therapeutics (NASDAQ:BTAI) and maintained an $11 price target.

Portfolio Pulse from richadhand@benzinga.com

August 28, 2023 | 10:29 am

RKDA

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Arcadia Biosciences (NASDAQ:RKDA) but lowers the price target from $15 to $10.

Portfolio Pulse from richadhand@benzinga.com

August 28, 2023 | 10:26 am

BSX

Citigroup analyst Joanne Wuensch has reiterated a 'Buy' rating on Boston Scientific (NYSE:BSX) and maintained a price target of $63.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 10:23 am